Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.The following is a summary of the Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript:
以下是Smith & Nephew Plc（SNN）2024年第三季度业绩会电话会议记录摘要：
Financial Performance:
财务表现:
Smith & Nephew reported Q3 revenue of $1.4 billion, marking a 4% underlying growth.
Projected annual underlying revenue growth revised to 4.5%, with an anticipated trading margin expansion of up to 50 basis points.
Smith & Nephew报告了第三季度营业收入为14亿美元，标志着基础增长率为4%。
预计年度基础营收增长率修订为4.5%，预期交易利润率将扩张至50个基点。
Business Progress:
业务进展：
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.
Implementation of robotics and innovation in orthopedics, such as the new CATALYSTEM in hips and advancements in the EVOS plating system, are enhancing Smith & Nephew's product portfolio.
Advanced Wound Management experienced its best growth quarter, driven by increased adoption across regions and categories.
在12点计划下，显着的运营改进已经被注意到，特别是由于产品供应和商业执行的改善，美国Recon业务已经增长。
实施了机器人技术和在骨科领域的创新，例如新的CAELSTEm髋关节产品和EVOS骨板系统的进步，正在增强Smith & Nephew的产品组合。
爱文思控股的高级伤口管理业务经历了其最佳增长季度，受到各地区和类别采用增加的推动。
Opportunities:
机会：
Growth momentum in established markets expected to continue with operational improvements and product innovations.
Advanced robotics and innovative products like CATALYSTEM hip systems and the EVOS plating system represent key growth drivers.
在成熟市场中，预计增长势头将继续，通过运营改进和产品创新。
爱文思控股和CATALYSTEm髋部系统等创新产品代表关键的增长驱动力。
Risks:
风险：
Projected slower growth from the Sports Medicine Volume-Based Procurement (VBP) in China, along with delayed benefits from expected volume increases, likely contributing more to margin pressure in 2025.
Persistent underperformance and low order expectations in China's recon business impacting near-term growth prospects.
预计中国体育医学成交量采购（VBP）的增长将放缓，加上预期成交量增加带来的效益延迟，可能更多地导致2025年利润压力。
中国的重建业务持续表现不佳和订单预期偏低，影响近期增长前景。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
